Mesenchymal Cell News Volume 3.00 | Jan 4 2011

    By
    Justin.choi
    -
    0
    18

    Mesenchymal Cell News 3.00, January 4, 2010.
    In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  EventsSubscribe  |  Unsubscribe

    TOP STORY

    Protein Wields Phosphate Group to Inhibit Cancer Metastasis 
    By sticking a chemical group to it at a specific site, a protein arrests an enzyme that may worsen and spread cancer. In addition to highlighting a novel anti-cancer pathway, researchers found that the same deactivation of the enzyme called EZH2 is necessary for the formation of bone-forming cells from the stem cells that make them and other tissues. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in the Nature Cell Biology]

    ON106-MethoCultWallchart-645x110

    SPECIAL FEATURE

    Facebook Cell Therapy News is now on Facebook! Join us.

    Twitter Follow us on Twitter! @MesenchymalCell

    Interested in recruiting talented individuals? Post your career opportunities in Mesenchymal Cell News at no cost . Contact us at info@connexoncreative.com

    SCIENCE NEWS

    New Test Announced for Major Killer of Lung Transplant Patients
    While the exact relationship between the mesenchymal stromal cells and bronchiolitis obliterans syndrome (BOS) remains unclear, doctors know that most of the cells originate with the donor and not the recipient. Researchers hope a new diagnostic tool they developed to predict BOS will allow doctors to intervene earlier and, ultimately, to provide life-saving treatments. [Press release from the University of Michigan Medical School discussing online prepublication in the American Journal of Respiratory and Critical Care Medicine]

    MesenCult®-XF Medium 
    Obtain more MSCs in fewer passages with
    MesenCult®-XF Medium
    by STEMCELL Technologies
    		 
     
    WATCH THE VIDEOSTEMCELL Technologies Inc
    		 

    CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

    CDK1-Dependent Phosphorylation of EZH2 Suppresses Methylation of H3K27 and Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells
    In human mesenchymal stem cells, activation of cyclin-dependent kinase 1 (CDK1) promoted mesenchymal stem cell differentiation into osteoblasts through phosphorylation of enhancer of zeste homologue 2 (EZH2) at Thr 487. [Nat Cell Biol]

    Mesenchymal Stromal Cells in Bronchoalveolar Lavage as Predictors of Bronchiolitis Obliterans Syndrome
    In this study, researchers investigated the association of number of mesenchymal stromal cells in bronchoalveolar lavage fluid with development of bronchiolitis obliterans syndrome in human lung transplant recipients. [Am J Respir Crit Care Med]

    Selective Targeting of Gold Nanorods at the Mitochondria of Cancer Cells: Implications for Cancer Therapy
    Researchers have observed that gold nanorods have distinct effects on cell viability via killing cancer cells while posing negligible impact on normal cells and mesenchymal stem cells. [Nano Lett]

    Chondrogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells on Polyhydroxyalkanoate (PHA) Scaffolds Coated with PHA Granule Binding Protein PhaP Fused with RGD Peptide
    Human bone marrow mesenchymal stem cells (hBMSCs) were inoculated on/in the scaffolds for formation of articular cartilages derived from chondrogenic differentiation of hBMSCs for cartilage tissue engineering. [ Biomaterials]

    The Metabolism of Human Mesenchymal Stem Cells During Proliferation and Differentiation
    The present investigation measured the oxygen consumption, glucose consumption and lactate production of human mesenchymal stem cells during proliferation and subsequent differentiation towards the osteogenic and chondrogenic lineages. [J Cell Physiol]

    Analysis of the Chondrogenic Potential and Secretome of Mesenchymal Stem Cells Derived from Human Umbilical Cord Stroma
    Mesenchymal stem cells (MSCs) from umbilical cord stroma were isolated by plastic adherence and characterized by flow cytometry, looking for cells positive for OCT3/4 and SSEA-4 as well as the classic MSC markers CD44, CD73, CD90, Ki67, CD105, and CD106 and negative for CD34 and CD45. [Stem Cells Dev]

    Mesenchymal Stem Cells Contribute to the Abnormal Bone Marrow Microenvironment in Patients with Chronic Idiopathic Neutropenia by Overproduction of Transforming Growth Factor-Beta1
    In this study, researchers investigated the possible involvement of bone marrow (BM) mesenchymal stem cells (MSCs) in the pathophysiology of chronic idiopathic neutropenia by assessing the frequency and function of BM MSCs in terms of the proliferative/clonogenic characteristics, the differentiation capacity, the potential to produce pro-inflammatory cytokines, and the ability to suppress T cell proliferation. [Stem Cells Dev]

    Human Mesenchymal Stem Cells Cultured with Salivary Gland Biopsies Adopt an Epithelial Phenotype
    Some reports indicated that mesenchymal stem cells (MSCs) possessed the potential to differentiate into epithelial cells. To test this hypothesis with human salivary gland epithelial cells, a coculture system containing two chambers separated by a polyester membrane was used to study the capacity of human MSCs to adopt an epithelial phenotype when cocultured with human salivary gland biopsies. [Stem Cells Dev]

    INDUSTRY NEWS

    Mesoblast Completes Acquisition of Angioblast
    Regenerative medicine company, Mesoblast Limited, announced that it had completed its acquisition of United States company Angioblast Systems Inc. with the issue of 90.8 million ordinary shares to former Angioblast security holders, increasing the total number of shares on offer to 253.8 million shares. [Mesoblast Limited Press Release]

    Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
    Juventas Therapeutics announced that the U.S. Food and Drug Administration authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia. [PR Newswire]

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)


    EVENTS

    Visit our events page to stay up to date with the latest events in the mesenchymal cell community.

    JOB OPPORTUNITIES

    Lab Technologist – Cell Separation (STEMCELL Technologies)

    Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

    Lab Technologist – Tissue Culture (STEMCELL Technologies)

    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Mesenchymal Cell News at no cost.

    Visit here to post your career opportunities.


    Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!



    Comments or Suggestions? Email info@connexoncreative.com with your feedback.


    Learn more about Mesenchymal Cell News: Archives  |  Events  |  Subscribe  |  Contact Us